NARCAN NASAL SPRAY Rx
Generic Name and Formulations:
Naloxone HCl 4mg; per spray; contains benzalkonium chloride.
Indications for NARCAN NASAL SPRAY:
Reversal of known or suspected opioid overdose, including respiratory and/or CNS depression.
Adults and Children:
Give as single spray intranasally into one nostril. May give additional doses (using a new nasal spray) every 2–3 mins in alternate nostrils if unresponsive or relapses into respiratory depression. Seek immediate emergency medical assistance after the first dose.
Not a substitute for emergency medical care. Known or suspected opioid dependence; abrupt reversal may precipitate acute withdrawal syndrome. Monitor patients with satisfactory response due to long duration of some narcotics. Post-op use in pre-existing cardiac disease. Have other resuscitative measures available. Elderly. Pregnancy; monitor for neonatal withdrawal symptoms. Nursing mothers.
Caution with cardiotoxic drugs. Incomplete reversal of buprenorphine or pentazocine; may require higher naloxone dose.
Increased BP, musculoskeletal pain, headache, nasal effects (eg, dryness, edema, congestion, inflammation); opioid withdrawal.
Single-dose nasal spray—2
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Testosterone Prescribing Trends in the United States Between 2002 and 2016
- The Future of Food and Drug Regulation: Trump Administration Proposes Reorganization of FDA, USDA
- Popliteal Sciatic Nerve Block May Increase Time to First Opioid Request in Diabetic Peripheral Neuropathy
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Subclinical Hypothyroidism: Controversies in Testing and Treatment